tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Purple Biotech granted new U.S. patent for NT219

Purple Biotech (PPBT) announced that the U.S. Patent and Trademark Office has issued a patent for NT219 used in combination with epidermal growth factor receptor, EGFR, antibodies for treating cancer patients who have acquired resistance to EGFR therapies. The patent, titled “Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer” addresses NT219 in combination with cetuximab as well as other EGFR antibodies such as panitumumab and necitumumab in treating tumors resistant to EGFR therapy and in preventing or delaying cancer tumor recurrence following cessation of treatment with an EGFR therapy.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1